Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
Last trade$16.03
Day change-$0.22 (-1.35%)
Day range$15.85 – $16.36
Volume1,391,034
Market cap$4.64B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$4.64B
Price / earnings
26.76×
Price / book
6.33×
Price / sales
3.77×
EV / sales
5.26×
EV / EBITDA
12.19×
Profitability
Earnings per share
$0.61
Return on assets
5.12%
Return on equity
23.66%
Dividend yield
0%
Liquidity and leverage
Debt / equity
3.06×
Current ratio
3.13×
Quick ratio
2.91×
Cash ratio
1.84×
Cash flow
Price / cash flow
14×
Price / free cash flow
34.27×
Free cash flow
$135.43M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SHC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$324.89M
$321.38M
$280.05M
$303.44M
$311.31M
$294.34M
$254.52M
$290.2M
Cost of revenue
$144.1M
$143.41M
$132.98M
$137.52M
$133.75M
$127.72M
$119.09M
$125.84M
Gross profit
$180.79M
$177.96M
$147.07M
$165.92M
$177.56M
$166.62M
$135.43M
$164.37M
Selling, general and administrative
$64.14M
$68.16M
$68.21M
$57.51M
$63.29M
$68.89M
$63.06M
$61.84M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$67.14M
$71.17M
$71.24M
-$4.41M
$66.38M
$112.19M
$109.33M
$77.22M
Operating income
$113.65M
$106.79M
$75.83M
$170.33M
$111.18M
$54.43M
$26.1M
$87.15M
Interest expense
-$34.12M
-$34.41M
-$34.75M
$120.67M
-$39.15M
-$40.65M
-$40.88M
$123.73M
Income before taxes
$83.73M
$78.05M
$42.61M
$70.5M
$72.94M
$18.9M
-$14.82M
$44.96M
Income taxes
$25.34M
$24.41M
$16.02M
$35.65M
$24.54M
$10.94M
-$1.56M
$32.64M
Net income
$58.39M
$53.64M
$26.59M
$34.85M
$48.4M
$7.96M
-$13.26M
$12.32M
Net income attributable to common shareholders
$58.39M
$53.64M
$26.59M
$34.85M
$48.4M
$7.96M
-$13.26M
$12.32M
EBITDA
$146.16M
$140.19M
$106.64M
$137.91M
$139.54M
$123.45M
$97.85M
$127.46M
Basic earnings per share
$0.20
$0.19
$0.09
$0.12
$0.17
$0.03
-$0.05
$0.04
Diluted earnings per share
$0.20
$0.19
$0.09
$0.12
$0.17
$0.03
-$0.05
$0.04
Recent news
Company coverage with links to the original publishers.
Options traders are pricing in significant volatility for Sotera Health Company (SHC) ahead of November 20, 2026, with the $5.00 call option showing unusually high implied volatility. However, analyst sentiment has turned slightly negative, with two analysts revising earnings estimates downward for the current quarter, reducing the consensus estimate from 27 cents to 26 cents per share. The company maintains a Zacks Rank #2 (Buy) rating despite the recent downward revisions.
Sotera Health reported Q3 2026 earnings of $0.29 per share, beating consensus estimates of $0.27, with revenues of $324.89 million also exceeding expectations. However, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends ahead of the earnings release. The stock has underperformed the S&P 500 year-to-date, gaining only 0.6% versus the market's 10.2% gain.
Sessa Capital invested $175.8 million in Sotera Health by purchasing 10.6 million shares in Q4, bringing its total stake to 20.55 million shares valued at $362.5 million. Despite a 21% stock decline, the investment signals confidence in the company's fundamentals, which include $1.2 billion in revenue and steady 20-year growth, though the stock faces headwinds from litigation risks, high leverage, and a recent secondary offering that flooded the market with shares.
Sotera Health Company announced the appointment of Kenneth D. Krause, Executive Vice President and CFO of Rollins, Inc., as a new independent director to its Board of Directors. Krause brings over 10 years of public company CFO experience and expertise in corporate strategy and capital allocation. Simultaneously, Constantine S. Mihas resigned from the Board effective March 16, 2026, due to a reduction in stockholder-designated director positions.
MIG Capital sold $37.41 million worth of Sotera Health shares (2.26 million shares) in Q4 2025, reducing its stake to 5.88% of AUM. Despite the trim, the fund maintains a significant position in the sterilization and lab testing company. Sotera posted its 20th consecutive year of revenue growth with 5.7% sales increase to $1.16 billion in 2025, while net income nearly doubled to $78 million. The company projects 5-6.5% revenue growth for 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.